In this PACULit update, Britany and Seth discuss Groninger and colleagues' pilot study on using virtual reality (VR) as a nonpharmacologic adjunct for outpatient management of chronic cancer pain. The single-arm trial enrolled 33 adult outpatients with persistent cancer pain to evaluate a phased VR dosing regimen over three weeks using the Meta Quest 2 headset. Primary outcome was pain intensity (numeric rating scale); secondary outcomes included PROMIS pain interference, patient satisfaction, and breakthrough opioid use. Results showed significant reductions in pain intensity and interference and an increase in satisfaction, with no significant change in opioid use. The episode covers dosing implications (twice-daily sessions in week two may be more effective), study strengths/limitations, and the need for larger randomized trials to confirm analgesic effects and potential opioid-sparing benefits. Contextual notes highlight the growing VR oncology literature and implications for outpatient pain management and multimodal analgesia.